Immupharma progresses with cancer treatment trials

13th Aug 2013 09:17

ImmuPharma, a drug developer, has reported that its lead cancer programme, IPP-204106, is progressing, and that trials are being conducted at three hospitals across Europe to identify the optimal dose for treating patients.IPP-204106 is 10 times more efficient that the previous Nucant version in pre-clinical cancer models, the group said. The trial will be followed by a Phase II efficacy study designed to treat various cancers, in approximately 30 patients, to identify appropriate biomarkers. Dr Robert Zimmer, MD, PhD, ImmuPharma's President and Chief Scientific Officer commented: "The clinical development of our cancer programme continues to be a key priority for ImmuPharma. We look forward to announcing interim results from the current trial in the near future."Patients that are being enrolled in the trial are in a serious condition, suffering from a range of cancers, all have metastasis (tumour spreading) and have failed their previous treatment, the company said. In the future the group plans to conduct more focused follow-up studies on patients with glioblastoma (brain tumour), metastatic melanoma, and pancreatic cancer where nucleolin plays a key role and who are showing the appropriate biomarkers. NR